Bull Harbor Capital LLC Takes $720,000 Position in Tenet Healthcare Corporation $THC

Bull Harbor Capital LLC bought a new stake in Tenet Healthcare Corporation (NYSE:THC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,815 shares of the company’s stock, valued at approximately $720,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. NewEdge Advisors LLC boosted its position in shares of Tenet Healthcare by 6.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,890 shares of the company’s stock valued at $389,000 after purchasing an additional 166 shares during the period. Jones Financial Companies Lllp boosted its position in Tenet Healthcare by 299.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,700 shares of the company’s stock worth $229,000 after purchasing an additional 1,274 shares during the period. Sivia Capital Partners LLC acquired a new stake in Tenet Healthcare during the second quarter valued at approximately $290,000. Quantbot Technologies LP bought a new position in Tenet Healthcare in the 2nd quarter valued at about $65,000. Finally, Amundi boosted its stake in Tenet Healthcare by 4,207.8% in the 2nd quarter. Amundi now owns 27,010 shares of the company’s stock worth $4,652,000 after purchasing an additional 26,383 shares during the period. 95.44% of the stock is owned by institutional investors and hedge funds.

Tenet Healthcare News Summary

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Analysts raised their price targets: Truist lifted its target to $290, while Guggenheim increased its target to $283 and Robert W. Baird raised its target to $280. The revisions reflect growing confidence in Tenet’s earnings outlook and imply additional upside from recent trading levels. Truist raises Tenet Healthcare price target Baird analyst comments on Tenet Healthcare Guggenheim analyst comments on Tenet Healthcare
• Positive Sentiment: Growth and momentum remain key attractions: Zacks highlighted Tenet’s above-average financial growth, strong momentum characteristics and potential appeal to growth-focused investors. These reports may support continued retail and quantitative-investor interest in THC. Three reasons growth investors may like Tenet Healthcare Tenet Healthcare momentum analysis
• Positive Sentiment: Fundamental performance supports the bullish case: Tenet’s latest quarterly results exceeded estimates, with EPS of $6.12 versus a $4.26 consensus and revenue of $6.04 billion versus $5.43 billion expected. The company also raised its 2026 outlook, strengthening the investment case behind the recent rally.
• Neutral Sentiment: Investor attention is elevated: Zacks reported increased user interest in Tenet and noted that the stock recently reached a 52-week high. However, the coverage is largely informational and does not represent a new company announcement or change in fundamentals. Zacks analysis of investor attention on Tenet Healthcare
• Negative Sentiment: Insider selling creates a modest overhang: EVP Paola Arbour sold 10,878 shares for approximately $2.65 million, while Director Christopher Lynch sold 3,837 shares worth about $934,000. Both transactions significantly reduced their holdings, although the sales may reflect personal financial planning rather than a negative view of Tenet’s prospects.

Insiders Place Their Bets

In other news, Director Christopher S. Lynch sold 3,837 shares of the stock in a transaction on Monday, July 27th. The shares were sold at an average price of $243.44, for a total value of $934,079.28. Following the completion of the sale, the director owned 9,568 shares of the company’s stock, valued at $2,329,233.92. This represents a 28.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director J Robert Kerrey sold 5,638 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the completion of the transaction, the director owned 16,804 shares of the company’s stock, valued at $2,932,634.08. This represents a 25.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 23,353 shares of company stock valued at $5,103,217. Insiders own 0.97% of the company’s stock.

Tenet Healthcare Price Performance

THC opened at $252.80 on Friday. The business’s fifty day simple moving average is $190.49 and its 200-day simple moving average is $198.96. Tenet Healthcare Corporation has a 12-month low of $156.71 and a 12-month high of $262.68. The company has a current ratio of 1.41, a quick ratio of 1.35 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $21.78 billion, a price-to-earnings ratio of 9.75, a PEG ratio of 0.98 and a beta of 1.27.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, July 23rd. The company reported $6.12 earnings per share for the quarter, topping the consensus estimate of $4.26 by $1.86. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%.The business had revenue of $6.04 billion during the quarter, compared to the consensus estimate of $5.43 billion. During the same period in the prior year, the company posted $4.02 EPS. The business’s quarterly revenue was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. On average, equities research analysts anticipate that Tenet Healthcare Corporation will post 21.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on THC shares. Guggenheim boosted their price objective on shares of Tenet Healthcare from $242.00 to $283.00 and gave the stock a “buy” rating in a report on Tuesday. Piper Sandler set a $308.00 price objective on shares of Tenet Healthcare in a research report on Monday. UBS Group upped their price objective on Tenet Healthcare from $288.00 to $308.00 and gave the stock a “buy” rating in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a research note on Monday. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $305.00 target price on shares of Tenet Healthcare in a research report on Tuesday. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $268.50.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.